［1］Chen W，Sun K，Zheng R，et al. Cancer incidence and mortality in China，2014.Chin J Cancer Res，2018，30（1）：1-12.

［2］Chen X，Li Y，Ouyang T，et al. Associations between RAD51D germline mutations and breast cancer risk and survival in BRCA1/2-negative breast cancers.Ann Oncol，2018，29（10）：2046-2051.

［3］Fan C，Zhang J，Ouyang T，et al. RAD50 germline mutations are associated with poor survival in BRCA1/2-negative breast cancer patients. Int J Cancer，2018，143（8）：1935-1942.

［4］Zhang J，Lin Y，Sun X J，et al. Biomarker assessment of the CBCSG006 trial：a randomized phase Ⅲtrial of cisplatin plus gemcitabine compared with paclitaxel plus gemcitabine as first-line therapy for patients with metastatic triple-negative breast cancer. Ann Oncol，2018，29（8）：1741-1747.

［5］Chen L，Yang L，Yao L，et al. Characterization of PIK3CA and PIK3R1 somatic mutations in Chinese breast cancer patients. Nat Commun，2018，9（1）：1357.

［6］Liu XY，Ma D，Xu XE，et al. Genomic landscape and endocrine-resistant subgroup in estrogen receptor-positive，progesterone receptor-negative，and HER2-negative breast cancer.Theranostics，2018，8（22）：6386-6399.

［7］Li H，Liu J，Chen J，et al. A serum microRNA signature predicts trastuzumab benefit in HER2-positive metastatic breast cancer patients. Nat Commun，2018，9（1）：1614.

［8］Sun C，Yang F，Zhang Y，et al. tRNA-Derived fragments as novel predictive biomarkers for trastuzumabresistant breast cancer. Cell Physiol Biochem，2018，49（2）：419-431.

［9］Lan B，Ma F，Zhai X，et al. The relationship between the CYP2D6 polymorphisms and tamoxifen efficacy in adjuvant endocrine therapy of breast cancer patients in Chinese Han population. Int J Cancer，2018，143（1）：184-189.

［10］Lan B，Ma F，Chen S，et al. Toremifene，rather than tamoxifen，might be a better option for the adjuvant endocrine therapy in CYP2D6*10T/T genotype breast cancer patients in China. Int J Cancer，2018，143（10）：2499-2504.

［11］Zhu Y，Liu Y，Zhang C，et al.Tamoxifen-resistant breast cancer cells are resistant to DNA-damaging chemotherapy because of upregulated BARD1 and BRCA1.Nat Commun，2018，9（1）：1595.

［12］Tong Y，Chen X，Fei X，et al. Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease？Eur J Cancer，2018，89：9-18.

［13］Chow L，Morita S，Chow C，et al. Neoadjuvant palbociclib on ER+ breast cancer（N007）：clinical response and EndoPredict's value.Endocr Relat Cancer，2018，25（2）：123-130.

［14］Zhang Y，Ji Y，Li J，et al. Sequential versus simultaneous use of chemotherapy and gonadotropin-releasing hormone agonist（GnRHa）among estrogen receptor（ER）-positive premenopausal breast cancer patients：effects on ovarian function，disease-free survival，and overall survival，Breast Cancer Res Treat，2018，168（3）：679-686.

［15］Chen J，Yao Q，Huang M，et al. A randomized Phase Ⅲ trial of neoadjuvant recombinant human endostatin，docetaxel and epirubicin as first-line therapy for patients with breast cancer（CBCRT01）. Int J Cancer，2018，142（10）：2130-2138.

［16］Wu X，Tang P，Li S，et al. A randomized and open-label phase Ⅱ trial reports the efficacy of neoadjuvant lobaplatin in breast cancer.Nat Commun，2018，9（1）：832.

［17］Gong C，Ma G，Hu X，et al. Pretreatment（18）F-FDG uptake heterogeneity predicts treatment outcome of first-line chemotherapy in patients with metastatic triple-negative breast cancer. Oncologist，2018，23（10）：1144-1152.

［18］Wang X，Ma J，Mei X，et al. Outcomes following salvage radiation and systemic therapy for isolated locoregionalrecurrence of breast cancer after mastectomy：impact of constructed biologic subtype. J Oncol，2018，2018：4736263.

［19］Zhu Q，Kirova Y M，Cao L，et al.Cardiotoxicity associated with radiotherapy in breast cancer：A question-based review with current literatures. Cancer Treat Rev，2018，68：9-15.

［20］Wang J，Zhou F，Li Z，et al. Pharmacological targeting of BET proteins attenuates radiation-induced lung fibrosis. Sci Rep，2018，8（1）：998.

［21］Mu J，Xi D，Ding Y，et al. Chair heterogeneity index：describing the dose heterogeneity inside the tumor volume where there is a boost volume.Sci Rep，2018，8（1）：9763.

［22］Yu T，Xu M，Sun T，et al.External-beam partial breast irradiation in a supine versus prone position after breast-conserving surgery for Chinese breast cancer patients. Sci Rep，2018，8（1）：15354.

［23］Wu SG，Zhang WW，Sun J Y，et al. Omission of postoperative radiotherapy in women aged 65 years or older with tubular carcinoma of the breast after breast-conserving surgery. Front Oncol，2018，8：190.

［24］Yuan L. et al. Comparison of sentinel lymph node detection performances using blue dye in conjunction with indocyanine green or radioisotope in breast cancer patients：a prospective single-center randomized study.Cancer Biol Med，2018，15（4）：452-460.

［25］Shen S. et al. Comparison of sentinel lymph node biopsy guided by blue dye with or without indocyanine green in early breast cancer. J Surg Oncol，2018，117（8）：1841-1847.

［26］Maimaitiaili A.，et al. Analysis of factors related to non-sentinel lymph node metastasis in 296 sentinel lymph node-positive Chinese breast cancer patients. Cancer Biol Med，2018，15（3）：282-289.

［27］Wu S. et al. Intraoperative touch imprint cytology in targeted axillary dissection after neoadjuvant chemotherapy for breast cancer patients with initial axillary metastasis. Ann SurgOncol，2018，25（11）：3150-3157.

［28］Huang NS. et al. Trends and clinicopathological predictors of axillary evaluation in ductal carcinoma in situ patients treated with breast-conserving therapy. Cancer Med，2018，7（1）：56-63.

［29］Xie X，et al. Preoperative prediction nomogram based on primary tumor miRNAs signature and clinical-related features for axillary lymph node metastasis in early-stage invasive breast cancer. Int J Cancer，2018，142（9）：1901-1910.

［30］Qi XW，et al. Clinical significance of internal mammary lymph node metastasis for breast cancer：Analysis of 337 breast cancer patients. Surg Oncol，2018，27（2）：185-191.

［31］Wang K，et al. Predictors of internal mammary lymph nodes（IMLN）metastasis and disease-free survival comparison between IMLN-positive and IMLN-negative breast cancer patients：Results from Western China Clinical Cooperation Group（WCCCG）database（CONSORT）. Medicine（Baltimore），2018，97（28）：e11296.

［32］Xiong Z，et al. Could local surgery improve survival in de novo stage Ⅳ breast cancer？BMC Cancer，2018，18（1）：885.

［33］Xiong Z，et al. Patterns of occurrence and outcomes of contralateral breast cancer：Analysis of SEER Data. J Clin Med，2018. 7（6）.

［34］Wang，J. et al. The Distribution and outcomes of the 21-Gene recurrence score in T1-T2N0 estrogen receptorpositive breast cancer with different histologicsubtypes. Front Genet，2018，9：638.

［35］Lei，Y.Y. et al. Adherence to the World Cancer Research Fund/American Institute for Cancer Research Guideline Is associated with better health-related quality of life among chinese patients with breast cancer. J Natl Compr Canc Netw，2018，16（3）：275-285.

［36］Cui，L. et al. Single institution analysis of incidence and risk factors for post-mastectomy pain syndrome. Sci Rep，2018，8（1）：11494.

［37］Li，W. et al. Precise pathologic diagnosis and individualized treatment improve the outcomes of invasive micropapillary carcinoma of the breast：a 12-year prospective clinical study. Mod Pathol，2018，31（6）：956-964.